Loading provider…
Loading provider…
Medical Oncology Physician in Raleigh, NC
NPI: 1265510416Primary Practice Location
DUKE UNIVERSITY HOSPITAL
2301 Erwin Rd, Durham, NC
Primary Employer
Duke Health Integrated Practice, Inc.
dhip.dukehealth.org
HQ Phone
Get MD Thomas's Phone Numberphone_androidMobile
Get MD Thomas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNC State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 67 | 122 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 44 | 64 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 27 | 27 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 13 | 45 |
Annual review of advances in non-small cell lung cancer research: a report for the year 2010.
Authors: Nirmal Veeramachaneni
Journal: J Thorac Oncol
Authors: Maria Baggstrom, George Simon, Neeta Somaiah
Journal: J Thorac Oncol
Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
Authors: James Urbanic, Lyudmila Bazhenova, Olwen Hahn, Steven Schild, Jeffrey Bogart
Publication Date: 2017-09-19
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, DRUG: Pembrolizumab, DRUG: Gemcitabine, DRUG: Pemetrexed Disodium, DRUG: Erlotinib Hydrochloride, RADIATION: Stereotactic Body Radiation Therapy (SBRT), RADIATION: Intensity-Modulated Radiation Therapy (IMRT), RADIATION: 3-Dimensional Conformal Radiation Therapy (3D-CRT)
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: carboplatin, DRUG: cisplatin, DRUG: paclitaxel, DRUG: pembrolizumab, DRUG: nab-paclitaxel, DRUG: pemetrexed, DRUG: canakinumab, DRUG: canakinumab-matching placebo
Lead Sponsor: Advaxis, Inc.
Intervention / Treatment: DRUG: Pembrolizumab, DRUG: ADXS-503